Liquidia Technologies News Today

MORRISVILLE, N.C., April 02, 2024 -- Liquidia Corporation announced today that Dr. Roger Jeffs, Chief Executive Officer, and Micheal Kaseta, Chief Operating Officer and Chief Financial Officer,...

On March 28, Judge Andrews removed the injunction issued in the Original Hatch Waxman LitigationOn March 29, Judge Bates denied United Therapeutics’ motion for temporary restraining order and...

Preparing to launch YUTREPIA™ inhalation powder upon final FDA approvalFederal Circuit rejected request by United Therapeutics for rehearing of earlier decision finding ‘793 Patent...

On February 20, the U.S. Supreme Court issued an order list that denied petitions for writ of certiorari filed in at least five intellectual property cases.

Last week, biopharmaceutical company Liquidia Technologies filed a petition for writ of certiorari with the U.S. Supreme Court to appeal a Federal Circuit ruling that affirmed induced infringement findings against Liquidia following the patent at issue being invalidated by the PTAB.

MORRISVILLE, N.C., Jan. 25, 2024 -- Liquidia Corporation announced today that the U.S. Food and Drug Administration provided an update on its review of the New Drug Application for YUTREPIA™ ...

Liquidia Corporation Announces Updates to Operations Leadership

Seeks dismissal of all claims related to ‘793 patent based on prior findings of invalidity which have been affirmed by the Federal CircuitRequests declaration that ‘327 patent is not infringed, is...

Seeks dismissal of all claims related to ‘793 patent based on prior findings of invalidity which have been affirmed by the Federal CircuitRequests...

Seeks dismissal of all claims related to ‘793 patent based on prior findings of invalidity which have been affirmed by the Federal CircuitRequests declaration that ‘327 patent is not infringed, is invalid and is